Clinical Efficacy of Romidepsin in Tumor Stage and Folliculotropic Mycosis Fungoides
Conclusion Romidepsin is active in subtypes of CTCL with less favorable outcomes, such as tumor-stage and folliculotropic mycosis fungoides. Teaser Patients with cutaneous T-cell lymphoma (CTCL) who have cutaneous tumors or folliculotropic disease involvement typically have poor prognoses. Analysis of the pivotal phase 2 trial of romidepsin in relapsed/refractory CTCL showed that single-agent romidepsin induced clinical response or stable disease in the majority of patients with cutaneous tumors and/or folliculotropic disease involvement, supporting its use in these patient populations.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
More News: Cancer & Oncology | Cutaneous T cell lymphoma | Leukemia | Lymphoma | Mycosis Fungoides | Myeloma | Skin | Study | T-cell Lymphoma